Achieving glycemic control is the most important factor for halting disease progression and limiting morbidity and mortality related to type 2 diabetes mellitus (T2DM). Despite availability of effective therapies, most patients do not achieve guideline-recommended glycated hemoglobin (HbA1c) targets. Multiple reasons are linked to this limited success, including clinical inertia, side effects, and patient treatment preferences. New classes of pharmacologic agents are being developed which can overcome many of these barriers while effectively attaining and maintaining glycemic control in T2DM.
Michael A. Nauck, MD, PhD, has disclosed the following relevant financial relationships.
Served as an advisor or consultant for: Amylin Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Diartis Pharmaceuticals; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; GlaxoSmithKline; Intarcia Therapeutics, Inc.; Janssen Global Services LLC; Lilly Deutschland GmbH; MannKind Corporation; Menarini Group; Merck Sharp & Dohme Corp.; Merck Sharp & Dohme GmbH; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi; Takeda Pharmaceuticals North America, Inc.; Versartis, Inc.; Wyeth Pharmaceuticals Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; GlaxoSmithKline; Lilly Deutschland GmbH; Menarini Group; Merck Sharp & Dohme GmbH; MetaCure Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Tolerx, Inc.
Melanie J. Davies, MD, FRCP, has disclosed the following relevant financial relationships.
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly Deutschland GmbH; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Sanofi
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly Deutschland GmbH; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Sanofi
Received grants for clinical research from: GlaxoSmithKline; Lilly Deutschland GmbH; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Pfizer Inc.; Sanofi
Kamlesh Khunti, MBChB, PhD, MD, has disclosed the following relevant financial relationships.
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Sanofi
Sten Madsbad, DMSc, has disclosed the following relevant financial relationships.
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Intarcia Therapeutics, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Lilly; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi
Received grants for clinical research from: Novo Nordisk
Luc Martinez, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Ipsen; Mayoly Spindler; Novo Nordisk; Pfizer Inc.; SERVIER
Tina Vilsbøll, MD, DMSc, has disclosed the following relevant financial relationships.
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Merck Sharp & Dohme Corp.; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Lilly Deutschland GmbH; Merck Sharp & Dohme Corp.; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Novo Nordisk